Partner news 15 November 2019 Syndesi Therapeutics announces successful completion of first-in-human Phase I study of novel SV2A modulator, SDI-118, in development for the treatment of cognitive impairment. Read full story
Partner news 4 November 2019 Vifor Pharma enters into commercial collaboration in the US with Janssen Read full story
